SANGAMO THERAPEUTICS, INC (SGMO) Form 8-K — Jun 23, 2026
$SGMOForm 8-KItems 1.01, 1.03, 2.03, 2.05Filed Jun 23, 2026, 8:45 AM ET0001193125-26-278582Original filing
Sangamo Therapeutics filed for Chapter 11 bankruptcy protection on June 23, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The company will continue to operate as a debtor-in-possession while seeking to maximize value for stakeholders, potentially through the sale of assets. This filing follows the company's delisting from Nasdaq in April 2026 due to failure to meet minimum bid price requirements.
Key figures
- Debt Amount
- 30000000
- Initial dip draw
- up to $10.5 million
- Workforce reduction
- 51 roles (40%)
- Restructuring expenses
- $3.0-4.0 million
- Lilly transaction value
- $50 million
- Astellas upfront payment
- $25 million
- Astellas milestone payments
- up to $25 million
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.